Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<sup>89</sup>Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8<sup>+</sup> immune responses to treatment with radiation and anti-CTLA4.

Npj imaging·2025
Same author

Reengineered Anti-CD4 Cys-diabody Variants for <sup>89</sup>Zr-immunoPET of CD4<sup>+</sup> T Cells in Immunocompetent Mice.

Molecular imaging and biology·2025
Same author

A pilot study of healing critical-sized calvarial defects by LL-37-generated monoosteophils.

Frontiers in bioengineering and biotechnology·2025
Same author

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

European journal of nuclear medicine and molecular imaging·2024
Same author

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.

Blood advances·2024
Same author

89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors.

Molecular cancer therapeutics·2024
Same journal

[<sup>68</sup>Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [<sup>68</sup>Ga]GaCl<sub>3</sub> from Cyclotron using Liquid Target: An Italian Experience.

Current radiopharmaceuticals·2025
Same journal

Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data.

Current radiopharmaceuticals·2025
Same journal

Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).

Current radiopharmaceuticals·2025
Same journal

Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [<sup>131</sup>I]Sodium Iodide.

Current radiopharmaceuticals·2025
Same journal

RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence.

Current radiopharmaceuticals·2025
Same journal

Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.

Current radiopharmaceuticals·2025
See all related articles

Related Experiment Video

Updated: May 26, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Protein targeting constructs in alpha therapy.

Tove Olafsen1, Jorgen Elgqvist, Anna M Wu

  • 1Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. tolafsen@mednet.ucla.edu

Current Radiopharmaceuticals
|December 29, 2011
PubMed
Summary
This summary is machine-generated.

Targeted alpha-particle therapy (TAT) uses advances in DNA technology and radionuclide chemistry to target cancer. This review discusses promising targeting constructs for future clinical use in radioimmunotherapy (RIT).

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: May 26, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

  • Nuclear medicine and oncology
  • Biotechnology and molecular engineering

Background:

  • Targeted alpha-particle therapy (TAT) leverages recombinant DNA technology and radionuclide chemistry for cancer treatment.
  • Advances in genomics and proteomics aid in identifying novel cancer targets.
  • Radioimmunotherapy (RIT) aims to enhance cancer cell delivery and efficacy while minimizing toxicity.

Purpose of the Study:

  • To review and discuss promising targeting constructs for future applications in targeted alpha-particle therapy (TAT).
  • To highlight challenges and potential solutions for clinical translation of TAT.

Main Methods:

  • Review of various targeting constructs, including antibody fragments (enzymatic and genetically engineered), affibodies, peptides, and liposomes.
  • Discussion of strategies to improve TAT efficacy, such as pretargeting and multidosing.
  • Analysis of factors limiting clinical translation, including radiolabel availability and half-lives.

Main Results:

  • Several targeting constructs show promise for future TAT applications.
  • Clinical studies to date are promising, but significant challenges remain for safety and economic feasibility.
  • Various approaches like size reduction, pretargeting, and multidosing are being investigated.

Conclusions:

  • Targeting constructs like antibody fragments, affibodies, and peptides are crucial for advancing TAT.
  • Overcoming challenges related to radiolabel availability and half-lives is essential for clinical success.
  • Continued research into novel constructs and delivery strategies is needed to make TAT safe and economically viable.